Canadian Urological Association guideline: Muscle-invasive bladder cancer
Canadian Urological Association Journal2019Vol. 13(8), pp. 230–238
Citations Over TimeTop 10% of 2019 papers
Girish S. Kulkarni, Peter C. Black, Srikala S. Sridhar, Anil Kapoor, Alexandre R. Zlotta, Bobby Shayegan, Ricardo Rendon, Peter Chung, Theodorus van der Kwast, Nimira Alimohamed, Yves Fradet, Wassim Kassouf
Abstract
On average, an estimated 9000 incident cases of bladder cancer are diagnosed in Canada annually.1 Of these, approximately 25% will be muscle-invasive at presentation. Muscle-invasive bladder cancer (MIBC) possesses an aggressive biology that portends metastatic disease. Overall, the five-year mortality of patients diagnosed with localized MIBC is approximately 40–50%.2,3 In the setting of metastatic disease, long-term survival is rare. To help streamline treatment and optimize care, the Canadian Urological Association (CUA) commissioned the creation of a national guideline on MIBC.
Related Papers
- → Bladder preservation protocols in the management of muscle-invasive bladder cancer: A systematic review(2018)2 cited
- → POD-09.06: Radical cystectomy in nonmuscle invasive bladder cancer(2007)
- Clinical study of partial cystectomy combined with chemotherapy for muscle-invasive bladder cancer(2012)
- → Chemo-radiation in Muscle Invasive Bladder Cancer(2021)
- → The Role of Palliative Cystectomy in Bladder Cancer(2021)